Expert Details
Pharmaceutical Discovery and Preclinical Development
ID: 732838
Illinois, USA
IVIG (Gammar-P IV ) Rhone Poulenc Rorer Marketed
AMP – 579 Rhone Poulenc Rorer Phase II
Fenofibrate (TriCor) Abbott in-licensed from Fournier. Over $1 Billion in annual sales.
ABT-538/ABT-378 (Kaletra) Abbott over $1 Billion in peak annual sales
Bimoclomol (ABT-822) in-licensed from Biorex Phase II.
Levosimendan (Simdax) from Orion Launched in 44 Co.
Zotarolimus (Endeavor stent), marketed
Bardoxolone methyl Phase III
Abt-719 Phase IIb
Atrasentan (ABT-627), Phase III
AbbVie Hep C Combination product (Viekria Pak) Approved
Delafloxacin (Baxdela) Approved
Amantadine (ADS-5102) Approved
Elagolix FDA Priority Review
SPECIAL PROJECTS
Integration of assets from BASF/Knoll
Due diligence – Kos Pharmaceuticals
Subject Matter Expert for FDA Advisory Committee Meeting on NDA 21-491.
Dyslipidemia – Discovery Project Team Leader. Lead candidate advanced into development.
Discovery Lead – Solvay Integration
Global Pharmaceutical Research and Dev. Lead – Grants and Donations
President / Vice-President Helping Hands Food Pantry Spring Grove IL
Lead Subject Matter Expert (LSME) for litigation defending a major University Hospital
AD HOC REVIEWER
American Journal of Physiology: Heart and Circulatory Section
American Journal of Physiology: Regulatory, Integrative, and Comp. Section
Life Sciences
Journal of Cardiovascular Pharmacology
Drug Development Research
Hypertension
Journal of Pharmacology and Experimental Therapeutics
Circulation
Inflammation Research
Clinical and Experimental Pharmacology and Physiology
British Journal of Pharmacology
Biochemical Pharmacology
Journal of Pharmacy and Pharmacology
American Journal of Physiology: Cell.
European Journal of Pharmacology
EDITORIAL BOARDS
Drug Development Research, 1998 to 2004
Journal of Pharmacology and Experimental Therapeutics, 2000 to 2017
Clinical and Experimental Pharmacology and Physiology, 2004 to 2012
Molecular Interventions, 2005 to 2011
The Pharmacologist, 2006 to 2008
CoPharm Global is a consulting firm providing an integrative pharmacologic assessment of individual compounds or projects from both a safety and efficacy perspective.
Work History
| Years | Employer | Title | Department |
|---|---|---|---|
| Years: 2015 to Present | Employer: Undisclosed | Title: Adjunct Professor | Department: |
Responsibilities:Adjunct professor. Information available upon request. |
|||
| Years | Employer | Title | Department |
| Years: 2003 to 2013 | Employer: | Title: Director | Department: |
Responsibilities:Lead a diversified pharmacology unit which provided pivotal datasets enabling advancement of Discovery compounds into early Clinical Development. Served as a member of the Discovery Leadership Team responsible for the scientific direction, budget, and promotions for 975 employees across multiple international research sites. Initiated and established a new research area (Renal) leveraging global academic collaborations, selected contract research organizations, and focused internal resources to advance new pharmacologic targets. Was the Discovery representative on the Renal Therapeutic Area Executive Committee (Discovery, Clinical Development, Regulatory, Marketing, and Commercial). Chosen as the GPRD Leader for the Grants and Donations Workstream (first of 8 to complete an integrated training/process matrix). Appointed as a Charter member of the Technical Assessment Team for Abbott BioVentures (Venture Capital Arm for pharmaceutical investments – Preclinical lead on a Series A financing). Major contributions to numerous in-licensing and acquisition opportunities. |
|||
| Years | Employer | Title | Department |
| Years: 2001 to 2003 | Employer: Integrative Pharmacology | Title: Senior Project Leader/ Department Manager | Department: |
Responsibilities:In addition to leading the efficacy and safety pharmacology functions of Integrative Pharmacology, significantly increased the Translational Medicine capabilities of Abbott Discovery. Specifically, built an Imaging team with greatly enhanced impact on the drug discovery process. Included capital budgets for new technology acquisition and facility renovations. |
|||
| Years | Employer | Title | Department |
| Years: 2001 to 2002 | Employer: Steering Committee | Title: Member and Sub-Team Leader | Department: Cardiovascular Strategic Task Force |
Responsibilities:Set CV Strategy across all Abbott Divisions (including integration of assets from Knoll) |
|||
| Years | Employer | Title | Department |
| Years: 2000 to 2001 | Employer: Steering Committee | Title: Project Leader / Department Manager | Department: Integrative Pharmacology |
Responsibilities:Integrative PharmacologyGlobal Pharmaceutical Research and Development Abbott Laboratories More information available upon request. |
|||
| Years | Employer | Title | Department |
| Years: 1999 to 2000 | Employer: Vascular Medicine Business Unit | Title: Discovery Representative, | Department: Vascular Medicine Franchise Leadership Team |
Responsibilities:Responsible for developing the Strategic Plan for the Vascular Medicine Business Unit. |
|||
| Years | Employer | Title | Department |
| Years: 1997 to 2001 | Employer: Steering Committee | Title: Discovery Representative, Collaborative Res. & Devel. Committee | Department: |
Responsibilities:Bimoclomol (BRLP-42, ABT-822)Abbott - Biorex (Veszprem, Hungary) Target: Diabetic Neuropathy |
|||
| Years | Employer | Title | Department |
| Years: 1996 to 2000 | Employer: Steering Committee | Title: Senior Group Leader | Department: |
Responsibilities:(7 Senior Staff, 11 B.S./M.S.) |
|||
| Years | Employer | Title | Department |
| Years: 1991 to 1996 | Employer: RHÔNE-POULENC RORER, INC. | Title: Senior Research Scientist, Associate Research Fellow | Department: |
Responsibilities:Senior Research Scientist, Associate Research Fellow |
|||
| Years | Employer | Title | Department |
| Years: 1991 to 1995 | Employer: St. Louis University | Title: Member and Research Advisor | Department: Dept. of Pharmacological and Physiological Science |
Responsibilities:Doctoral Dissertation |
|||
Career Accomplishments
| Associations / Societies |
|---|
| MEMBERSHIPS - SOCIETY AND PROFESSIONAL Phi Eta Sigma National Honor Society American Heart Association American Physiological Society American Society for Pharmacology and Experimental Therapeutics International Society for Magnetic Resonance in Medicine |
| Awards / Recognition |
|---|
| AWARDS – HONORS – GRANTS B.S. - Magna Cum Laude North Carolina State University University of Iowa Graduate College Fellowship NIH Pharmacologic Sciences Training Grant NIH Cardiovascular Research Training Grant Proctor and Gamble Professional Opportunity Award Fellow: American Heart Association APS Selection Committee for the Berliner Award (Renal) Fellow: APS Cardiovascular Section ASPET Executive Committee: Division of Drug Discovery, Development, and Regulatory Affairs (Charter Member) ASPET Program Committee APS Section Program Committee: Neural Control and Autonomic Reg ASPET Division of Drug Discovery, Develop. and Reg. Affairs Named Investigator / Steering Cmte Member Direct costs funded at $680,000 (4years). Michigan State Pharmacology Masters Program Advisory Cmte Secretary/Treasurer ASPET |
| Publications and Patents Summary |
|---|
| Over 100 publications. Available upon request. |
Additional Experience
| Expert Witness Experience |
|---|
| Subject matter expert in defending Medical Clinic / Major University Hospital (settlement reached) Subject matter expert in pharmaceutical liability case (2.2 billion settlement reached) |
| Training / Seminars |
|---|
| CORPORATE TRAINING Knowing Research and Development Managing Your Team Pharmacokinetics and Metabolism Positive Power and Influence Recombinant DNA Techniques Advanced Program for Managers Performance Excellence Producing Results with Others II Business Without Borders Intro. Pharmaceutical Law (new modules annually) |
| Vendor Selection |
|---|
| Responsible for identifying and approving many contract research organizations (both non-GLP and GLP). |